SPRAVATO — Sales to customers (Note 9)
Johnson & Johnson SPRAVATO — Sales to customers (Note 9) decreased by 7.0% to $468.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 46.3%, from $320.00M to $468.00M. Over 3 years (FY 2022 to FY 2025), SPRAVATO — Sales to customers (Note 9) shows an upward trend with a 65.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand, successful commercial execution, or expanded patient access, while a decrease may signal market saturation, increased competition, or patent expiration.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line to extern...
Peer comparison
Comparable to specific product revenue line items reported by other large-cap pharmaceutical companies, often found in segment disclosures or product-specific revenue tables.
jnj_segment_spravato_sales_to_customers_note_9Historical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $70.00M | $85.00M | $100.00M | $119.00M | $131.00M | $169.00M | $183.00M | $206.00M | $225.00M | $271.00M | $284.00M | $297.00M | $320.00M | $414.00M | $459.00M | $503.00M | $468.00M |
| QoQ Change | — | +21.4% | +17.6% | +19.0% | +10.1% | +29.0% | +8.3% | +12.6% | +9.2% | +20.4% | +4.8% | +4.6% | +7.7% | +29.4% | +10.9% | +9.6% | -7.0% |
| YoY Change | — | — | — | — | +87.1% | +98.8% | +83.0% | +73.1% | +71.8% | +60.4% | +55.2% | +44.2% | +42.2% | +52.8% | +61.6% | +69.4% | +46.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's spravato — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported spravato — sales to customers (note 9) of $468.00M in Q1 2026.
- How has Johnson & Johnson's spravato — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's spravato — sales to customers (note 9) increased by 46.3% year-over-year, from $320.00M to $468.00M.
- What is the long-term trend for Johnson & Johnson's spravato — sales to customers (note 9)?
- Over 3 years (2022 to 2025), Johnson & Johnson's spravato — sales to customers (note 9) has grown at a 65.5% compound annual growth rate (CAGR), from $374.00M to $1.70B.
- What does spravato — sales to customers (note 9) mean?
- The total revenue earned from selling a specific pharmaceutical product to customers.